Type 2 Diabetes (T2D)

Type 2 Diabetes (T2D)

Type 2 diabetes (T2D) has been recognized as a bi hormonal disorder, with insulin and glucagon exerting opposite effects on glucose metabolism. Lang, et al., (2015). GLP-1-based diabetes therapies affect glucose control through several mechanisms, including slowed gastric emptying, regulation of postprandial glucagon, reduction of food intake, and enhancement of glucose-dependent insulin secretion without the risk of hypoglycemia. Chia-Hung, et al., (2015). One of the medications in the GLP-1 class is Exenatide with a generic name Byetta. In clinical trials, Sub Q injection of Exenatide (Byetta) 5 or 10ug was taken twice daily before the two largest meals of the day produced a modest decrease in fasting blood glucose and a large decrease in postprandial blood glucose. However, patients did not gain any weight and much lost weight. Rosenthal, & Burchum (2021).